Ocular Therapeutix reports net loss of $10 million in second quarter

Ocular Therapeutix reported a net loss of $10 million, or $0.45 per share, in the second quarter compared with a net loss of $6.4 million, or $2.10 per share, in the same quarter of 2014, according to a press release. Operating expenses increased to $10.1 million from $6 million, and research and development expenses increased to $6.7 million from $4.3 million. The increase was attributed to personnel costs and clinical trials of Dextenza and OTX-TP.